Assessment of Ceftazidime-Avibactam 30/20 μg Disk Content Versus MIC Results When Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

about

Assessment of Ceftazidime-Avibactam 30/20 μg Disk Content Versus MIC Results When Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Item

http://www.wikidata.org/entity/Q52644115

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Assessment of Ceftazidime-Avib ...... ae and Pseudomonas aeruginosa.

@en

Assessment of Ceftazidime-Avib ...... ae and Pseudomonas aeruginosa.

@nl

type

Item

label

Assessment of Ceftazidime-Avib ...... ae and Pseudomonas aeruginosa.

@en

Assessment of Ceftazidime-Avib ...... ae and Pseudomonas aeruginosa.

@nl

prefLabel

Assessment of Ceftazidime-Avib ...... ae and Pseudomonas aeruginosa.

@en

Assessment of Ceftazidime-Avib ...... ae and Pseudomonas aeruginosa.

@nl

P1476

Assessment of Ceftazidime-Avib ...... ae and Pseudomonas aeruginosa.

@en

P2093

Gregory G Stone

http://www.w3.org/2001/XMLSchema#string

Ian A Critchley

http://www.w3.org/2001/XMLSchema#string

Michael D Huband

http://www.w3.org/2001/XMLSchema#string

Paul R Rhomberg

http://www.w3.org/2001/XMLSchema#string

Ronald N Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Setting and revising antibacterial susceptibility breakpoints.

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.

Determination of disk diffusion susceptibility testing interpretive criteria using model-based analysis: development and implementation.

Emerging Resistance, New Antimicrobial Agents … but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.

Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resis

Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.

Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.

Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

P31

scholarly article

P356

10.1128/JCM.01960-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Helio S Sader

Robert K Flamm

P577

2018-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29563198

http://www.w3.org/2001/XMLSchema#string

P921

Pseudomonas aeruginosa

P932

5971542

http://www.w3.org/2001/XMLSchema#string